<!DOCTYPE html><html><head><meta charset="utf-8"><style>body {
  max-width: 980px;
  border: 1px solid #ddd;
  outline: 1300px solid #fff;
  margin: 16px auto;
}

body .markdown-body
{
  padding: 45px;
}

@font-face {
  font-family: fontawesome-mini;
  src: url(data:font/woff;charset=utf-8;base64,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) format('woff');
}

.markdown-body {
  font-family: sans-serif;
  -ms-text-size-adjust: 100%;
  -webkit-text-size-adjust: 100%;
  color: #333333;
  overflow: hidden;
  font-family: "Helvetica Neue", Helvetica, "Segoe UI", Arial, freesans, sans-serif;
  font-size: 16px;
  line-height: 1.6;
  word-wrap: break-word;
}

.markdown-body a {
  background: transparent;
}

.markdown-body a:active,
.markdown-body a:hover {
  outline: 0;
}

.markdown-body b,
.markdown-body strong {
  font-weight: bold;
}

.markdown-body mark {
  background: #ff0;
  color: #000;
  font-style: italic;
  font-weight: bold;
}

.markdown-body sub,
.markdown-body sup {
  font-size: 75%;
  line-height: 0;
  position: relative;
  vertical-align: baseline;
}
.markdown-body sup {
  top: -0.5em;
}
.markdown-body sub {
  bottom: -0.25em;
}

.markdown-body h1 {
  font-size: 2em;
  margin: 0.67em 0;
}

.markdown-body img {
  border: 0;
}

.markdown-body hr {
  -moz-box-sizing: content-box;
  box-sizing: content-box;
  height: 0;
}

.markdown-body pre {
  overflow: auto;
}

.markdown-body code,
.markdown-body kbd,
.markdown-body pre,
.markdown-body samp {
  font-family: monospace, monospace;
  font-size: 1em;
}

.markdown-body input {
  color: inherit;
  font: inherit;
  margin: 0;
}

.markdown-body html input[disabled] {
  cursor: default;
}

.markdown-body input {
  line-height: normal;
}

.markdown-body input[type="checkbox"] {
  box-sizing: border-box;
  padding: 0;
}

.markdown-body table {
  border-collapse: collapse;
  border-spacing: 0;
}

.markdown-body td,
.markdown-body th {
  padding: 0;
}

.markdown-body .codehilitetable {
  border: 0;
  border-spacing: 0;
}

.markdown-body .codehilitetable tr {
  border: 0;
}

.markdown-body .codehilitetable pre,
.markdown-body .codehilitetable div.codehilite {
  margin: 0;
}

.markdown-body .linenos,
.markdown-body .code,
.markdown-body .codehilitetable td {
  border: 0;
  padding: 0;
}

.markdown-body td:not(.linenos) .linenodiv {
  padding: 0 !important;
}

.markdown-body .code {
  width: 100%;
}

.markdown-body .linenos div pre,
.markdown-body .linenodiv pre,
.markdown-body .linenodiv {
  border: 0;
  -webkit-border-radius: 0;
  -moz-border-radius: 0;
  border-radius: 0;
  -webkit-border-top-left-radius: 3px;
  -webkit-border-bottom-left-radius: 3px;
  -moz-border-radius-topleft: 3px;
  -moz-border-radius-bottomleft: 3px;
  border-top-left-radius: 3px;
  border-bottom-left-radius: 3px;
}

.markdown-body .code div pre,
.markdown-body .code div {
  border: 0;
  -webkit-border-radius: 0;
  -moz-border-radius: 0;
  border-radius: 0;
  -webkit-border-top-right-radius: 3px;
  -webkit-border-bottom-right-radius: 3px;
  -moz-border-radius-topright: 3px;
  -moz-border-radius-bottomright: 3px;
  border-top-right-radius: 3px;
  border-bottom-right-radius: 3px;
}

.markdown-body * {
  -moz-box-sizing: border-box;
  box-sizing: border-box;
}

.markdown-body input {
  font: 13px Helvetica, arial, freesans, clean, sans-serif, "Segoe UI Emoji", "Segoe UI Symbol";
  line-height: 1.4;
}

.markdown-body a {
  color: #4183c4;
  text-decoration: none;
}

.markdown-body a:hover,
.markdown-body a:focus,
.markdown-body a:active {
  text-decoration: underline;
}

.markdown-body hr {
  height: 0;
  margin: 15px 0;
  overflow: hidden;
  background: transparent;
  border: 0;
  border-bottom: 1px solid #ddd;
}

.markdown-body hr:before,
.markdown-body hr:after {
  display: table;
  content: " ";
}

.markdown-body hr:after {
  clear: both;
}

.markdown-body h1,
.markdown-body h2,
.markdown-body h3,
.markdown-body h4,
.markdown-body h5,
.markdown-body h6 {
  margin-top: 15px;
  margin-bottom: 15px;
  line-height: 1.1;
}

.markdown-body h1 {
  font-size: 30px;
}

.markdown-body h2 {
  font-size: 21px;
}

.markdown-body h3 {
  font-size: 16px;
}

.markdown-body h4 {
  font-size: 14px;
}

.markdown-body h5 {
  font-size: 12px;
}

.markdown-body h6 {
  font-size: 11px;
}

.markdown-body blockquote {
  margin: 0;
}

.markdown-body ul,
.markdown-body ol {
  padding: 0;
  margin-top: 0;
  margin-bottom: 0;
}

.markdown-body ol ol,
.markdown-body ul ol {
  list-style-type: lower-roman;
}

.markdown-body ul ul ol,
.markdown-body ul ol ol,
.markdown-body ol ul ol,
.markdown-body ol ol ol {
  list-style-type: lower-alpha;
}

.markdown-body dd {
  margin-left: 0;
}

.markdown-body code,
.markdown-body pre,
.markdown-body samp {
  font-family: Consolas, "Liberation Mono", Menlo, Courier, monospace;
  font-size: 12px;
}

.markdown-body pre {
  margin-top: 0;
  margin-bottom: 0;
}

.markdown-body kbd {
  background-color: #e7e7e7;
  background-image: -moz-linear-gradient(#fefefe, #e7e7e7);
  background-image: -webkit-linear-gradient(#fefefe, #e7e7e7);
  background-image: linear-gradient(#fefefe, #e7e7e7);
  background-repeat: repeat-x;
  border-radius: 2px;
  border: 1px solid #cfcfcf;
  color: #000;
  padding: 3px 5px;
  line-height: 10px;
  font: 11px Consolas, "Liberation Mono", Menlo, Courier, monospace;
  display: inline-block;
}

.markdown-body>*:first-child {
  margin-top: 0 !important;
}

.markdown-body>*:last-child {
  margin-bottom: 0 !important;
}

.markdown-body .headerlink {
  font: normal 400 16px fontawesome-mini;
  vertical-align: middle;
  margin-left: -16px;
  float: left;
  display: inline-block;
  text-decoration: none;
  opacity: 0;
  color: #333;
}

.markdown-body .headerlink:focus {
  outline: none;
}

.markdown-body h1 .headerlink {
  margin-top: 0.8rem;
}

.markdown-body h2 .headerlink,
.markdown-body h3 .headerlink {
  margin-top: 0.6rem;
}

.markdown-body h4 .headerlink {
  margin-top: 0.2rem;
}

.markdown-body h5 .headerlink,
.markdown-body h6 .headerlink {
  margin-top: 0;
}

.markdown-body .headerlink:hover,
.markdown-body h1:hover .headerlink,
.markdown-body h2:hover .headerlink,
.markdown-body h3:hover .headerlink,
.markdown-body h4:hover .headerlink,
.markdown-body h5:hover .headerlink,
.markdown-body h6:hover .headerlink {
  opacity: 1;
  text-decoration: none;
}

.markdown-body h1 {
  padding-bottom: 0.3em;
  font-size: 2.25em;
  line-height: 1.2;
  border-bottom: 1px solid #eee;
}

.markdown-body h2 {
  padding-bottom: 0.3em;
  font-size: 1.75em;
  line-height: 1.225;
  border-bottom: 1px solid #eee;
}

.markdown-body h3 {
  font-size: 1.5em;
  line-height: 1.43;
}

.markdown-body h4 {
  font-size: 1.25em;
}

.markdown-body h5 {
  font-size: 1em;
}

.markdown-body h6 {
  font-size: 1em;
  color: #777;
}

.markdown-body p,
.markdown-body blockquote,
.markdown-body ul,
.markdown-body ol,
.markdown-body dl,
.markdown-body table,
.markdown-body pre,
.markdown-body .admonition {
  margin-top: 0;
  margin-bottom: 16px;
}

.markdown-body hr {
  height: 4px;
  padding: 0;
  margin: 16px 0;
  background-color: #e7e7e7;
  border: 0 none;
}

.markdown-body ul,
.markdown-body ol {
  padding-left: 2em;
}

.markdown-body ul ul,
.markdown-body ul ol,
.markdown-body ol ol,
.markdown-body ol ul {
  margin-top: 0;
  margin-bottom: 0;
}

.markdown-body li>p {
  margin-top: 16px;
}

.markdown-body dl {
  padding: 0;
}

.markdown-body dl dt {
  padding: 0;
  margin-top: 16px;
  font-size: 1em;
  font-style: italic;
  font-weight: bold;
}

.markdown-body dl dd {
  padding: 0 16px;
  margin-bottom: 16px;
}

.markdown-body blockquote {
  padding: 0 15px;
  color: #777;
  border-left: 4px solid #ddd;
}

.markdown-body blockquote>:first-child {
  margin-top: 0;
}

.markdown-body blockquote>:last-child {
  margin-bottom: 0;
}

.markdown-body table {
  display: block;
  width: 100%;
  overflow: auto;
  word-break: normal;
  word-break: keep-all;
}

.markdown-body table th {
  font-weight: bold;
}

.markdown-body table th,
.markdown-body table td {
  padding: 6px 13px;
  border: 1px solid #ddd;
}

.markdown-body table tr {
  background-color: #fff;
  border-top: 1px solid #ccc;
}

.markdown-body table tr:nth-child(2n) {
  background-color: #f8f8f8;
}

.markdown-body img {
  max-width: 100%;
  -moz-box-sizing: border-box;
  box-sizing: border-box;
}

.markdown-body code,
.markdown-body samp {
  padding: 0;
  padding-top: 0.2em;
  padding-bottom: 0.2em;
  margin: 0;
  font-size: 85%;
  background-color: rgba(0,0,0,0.04);
  border-radius: 3px;
}

.markdown-body code:before,
.markdown-body code:after {
  letter-spacing: -0.2em;
  content: "\00a0";
}

.markdown-body pre>code {
  padding: 0;
  margin: 0;
  font-size: 100%;
  word-break: normal;
  white-space: pre;
  background: transparent;
  border: 0;
}

.markdown-body .codehilite {
  margin-bottom: 16px;
}

.markdown-body .codehilite pre,
.markdown-body pre {
  padding: 16px;
  overflow: auto;
  font-size: 85%;
  line-height: 1.45;
  background-color: #f7f7f7;
  border-radius: 3px;
}

.markdown-body .codehilite pre {
  margin-bottom: 0;
  word-break: normal;
}

.markdown-body pre {
  word-wrap: normal;
}

.markdown-body pre code {
  display: inline;
  max-width: initial;
  padding: 0;
  margin: 0;
  overflow: initial;
  line-height: inherit;
  word-wrap: normal;
  background-color: transparent;
  border: 0;
}

.markdown-body pre code:before,
.markdown-body pre code:after {
  content: normal;
}

/* Admonition */
.markdown-body .admonition {
  -webkit-border-radius: 3px;
  -moz-border-radius: 3px;
  position: relative;
  border-radius: 3px;
  border: 1px solid #e0e0e0;
  border-left: 6px solid #333;
  padding: 10px 10px 10px 30px;
}

.markdown-body .admonition table {
  color: #333;
}

.markdown-body .admonition p {
  padding: 0;
}

.markdown-body .admonition-title {
  font-weight: bold;
  margin: 0;
}

.markdown-body .admonition>.admonition-title {
  color: #333;
}

.markdown-body .attention>.admonition-title {
  color: #a6d796;
}

.markdown-body .caution>.admonition-title {
  color: #d7a796;
}

.markdown-body .hint>.admonition-title {
  color: #96c6d7;
}

.markdown-body .danger>.admonition-title {
  color: #c25f77;
}

.markdown-body .question>.admonition-title {
  color: #96a6d7;
}

.markdown-body .note>.admonition-title {
  color: #d7c896;
}

.markdown-body .admonition:before,
.markdown-body .attention:before,
.markdown-body .caution:before,
.markdown-body .hint:before,
.markdown-body .danger:before,
.markdown-body .question:before,
.markdown-body .note:before {
  font: normal normal 16px fontawesome-mini;
  -moz-osx-font-smoothing: grayscale;
  -webkit-user-select: none;
  -moz-user-select: none;
  -ms-user-select: none;
  user-select: none;
  line-height: 1.5;
  color: #333;
  position: absolute;
  left: 0;
  top: 0;
  padding-top: 10px;
  padding-left: 10px;
}

.markdown-body .admonition:before {
  content: "\f056\00a0";
  color: 333;
}

.markdown-body .attention:before {
  content: "\f058\00a0";
  color: #a6d796;
}

.markdown-body .caution:before {
  content: "\f06a\00a0";
  color: #d7a796;
}

.markdown-body .hint:before {
  content: "\f05a\00a0";
  color: #96c6d7;
}

.markdown-body .danger:before {
  content: "\f057\00a0";
  color: #c25f77;
}

.markdown-body .question:before {
  content: "\f059\00a0";
  color: #96a6d7;
}

.markdown-body .note:before {
  content: "\f040\00a0";
  color: #d7c896;
}

.markdown-body .admonition::after {
  content: normal;
}

.markdown-body .attention {
  border-left: 6px solid #a6d796;
}

.markdown-body .caution {
  border-left: 6px solid #d7a796;
}

.markdown-body .hint {
  border-left: 6px solid #96c6d7;
}

.markdown-body .danger {
  border-left: 6px solid #c25f77;
}

.markdown-body .question {
  border-left: 6px solid #96a6d7;
}

.markdown-body .note {
  border-left: 6px solid #d7c896;
}

.markdown-body .admonition>*:first-child {
  margin-top: 0 !important;
}

.markdown-body .admonition>*:last-child {
  margin-bottom: 0 !important;
}

/* progress bar*/
.markdown-body .progress {
  display: block;
  width: 300px;
  margin: 10px 0;
  height: 24px;
  -webkit-border-radius: 3px;
  -moz-border-radius: 3px;
  border-radius: 3px;
  background-color: #ededed;
  position: relative;
  box-shadow: inset -1px 1px 3px rgba(0, 0, 0, .1);
}

.markdown-body .progress-label {
  position: absolute;
  text-align: center;
  font-weight: bold;
  width: 100%; margin: 0;
  line-height: 24px;
  color: #333;
  text-shadow: 1px 1px 0 #fefefe, -1px -1px 0 #fefefe, -1px 1px 0 #fefefe, 1px -1px 0 #fefefe, 0 1px 0 #fefefe, 0 -1px 0 #fefefe, 1px 0 0 #fefefe, -1px 0 0 #fefefe, 1px 1px 2px #000;
  -webkit-font-smoothing: antialiased !important;
  white-space: nowrap;
  overflow: hidden;
}

.markdown-body .progress-bar {
  height: 24px;
  float: left;
  -webkit-border-radius: 3px;
  -moz-border-radius: 3px;
  border-radius: 3px;
  background-color: #96c6d7;
  box-shadow: inset 0 1px 0 rgba(255, 255, 255, .5), inset 0 -1px 0 rgba(0, 0, 0, .1);
  background-size: 30px 30px;
  background-image: -webkit-linear-gradient(
    135deg, rgba(255, 255, 255, .4) 27%,
    transparent 27%,
    transparent 52%, rgba(255, 255, 255, .4) 52%,
    rgba(255, 255, 255, .4) 77%,
    transparent 77%, transparent
  );
  background-image: -moz-linear-gradient(
    135deg,
    rgba(255, 255, 255, .4) 27%, transparent 27%,
    transparent 52%, rgba(255, 255, 255, .4) 52%,
    rgba(255, 255, 255, .4) 77%, transparent 77%,
    transparent
  );
  background-image: -ms-linear-gradient(
    135deg,
    rgba(255, 255, 255, .4) 27%, transparent 27%,
    transparent 52%, rgba(255, 255, 255, .4) 52%,
    rgba(255, 255, 255, .4) 77%, transparent 77%,
    transparent
  );
  background-image: -o-linear-gradient(
    135deg,
    rgba(255, 255, 255, .4) 27%, transparent 27%,
    transparent 52%, rgba(255, 255, 255, .4) 52%,
    rgba(255, 255, 255, .4) 77%, transparent 77%,
    transparent
  );
  background-image: linear-gradient(
    135deg,
    rgba(255, 255, 255, .4) 27%, transparent 27%,
    transparent 52%, rgba(255, 255, 255, .4) 52%,
    rgba(255, 255, 255, .4) 77%, transparent 77%,
    transparent
  );
}

.markdown-body .progress-100plus .progress-bar {
  background-color: #a6d796;
}

.markdown-body .progress-80plus .progress-bar {
  background-color: #c6d796;
}

.markdown-body .progress-60plus .progress-bar {
  background-color: #d7c896;
}

.markdown-body .progress-40plus .progress-bar {
  background-color: #d7a796;
}

.markdown-body .progress-20plus .progress-bar {
  background-color: #d796a6;
}

.markdown-body .progress-0plus .progress-bar {
  background-color: #c25f77;
}

.markdown-body .candystripe-animate .progress-bar{
  -webkit-animation: animate-stripes 3s linear infinite;
  -moz-animation: animate-stripes 3s linear infinite;
  animation: animate-stripes 3s linear infinite;
}

@-webkit-keyframes animate-stripes {
  0% {
    background-position: 0 0;
  }

  100% {
    background-position: 60px 0;
  }
}

@-moz-keyframes animate-stripes {
  0% {
    background-position: 0 0;
  }

  100% {
    background-position: 60px 0;
  }
}

@keyframes animate-stripes {
  0% {
    background-position: 0 0;
  }

  100% {
    background-position: 60px 0;
  }
}

.markdown-body .gloss .progress-bar {
  box-shadow:
    inset 0 4px 12px rgba(255, 255, 255, .7),
    inset 0 -12px 0 rgba(0, 0, 0, .05);
}

/* Multimarkdown Critic Blocks */
.markdown-body .critic_mark {
  background: #ff0;
}

.markdown-body .critic_delete {
  color: #c82829;
  text-decoration: line-through;
}

.markdown-body .critic_insert {
  color: #718c00 ;
  text-decoration: underline;
}

.markdown-body .critic_comment {
  color: #8e908c;
  font-style: italic;
}

.markdown-body .headeranchor {
  font: normal normal 16px fontawesome-mini;
  line-height: 1;
  display: inline-block;
  text-decoration: none;
  -webkit-font-smoothing: antialiased;
  -moz-osx-font-smoothing: grayscale;
  -webkit-user-select: none;
  -moz-user-select: none;
  -ms-user-select: none;
  user-select: none;
}

.headeranchor:before {
  content: '\e157';
}

.markdown-body .task-list-item {
  list-style-type: none;
}

.markdown-body .task-list-item+.task-list-item {
  margin-top: 3px;
}

.markdown-body .task-list-item input {
  margin: 0 4px 0.25em -20px;
  vertical-align: middle;
}

/* Media */
@media only screen and (min-width: 480px) {
  .markdown-body {
    font-size:14px;
  }
}

@media only screen and (min-width: 768px) {
  .markdown-body {
    font-size:16px;
  }
}

@media print {
  .markdown-body * {
    background: transparent !important;
    color: black !important;
    filter:none !important;
    -ms-filter: none !important;
  }

  .markdown-body {
    font-size:12pt;
    max-width:100%;
    outline:none;
    border: 0;
  }

  .markdown-body a,
  .markdown-body a:visited {
    text-decoration: underline;
  }

  .markdown-body .headeranchor-link {
    display: none;
  }

  .markdown-body a[href]:after {
    content: " (" attr(href) ")";
  }

  .markdown-body abbr[title]:after {
    content: " (" attr(title) ")";
  }

  .markdown-body .ir a:after,
  .markdown-body a[href^="javascript:"]:after,
  .markdown-body a[href^="#"]:after {
    content: "";
  }

  .markdown-body pre {
    white-space: pre;
    white-space: pre-wrap;
    word-wrap: break-word;
  }

  .markdown-body pre,
  .markdown-body blockquote {
    border: 1px solid #999;
    padding-right: 1em;
    page-break-inside: avoid;
  }

  .markdown-body .progress,
  .markdown-body .progress-bar {
    -moz-box-shadow: none;
    -webkit-box-shadow: none;
    box-shadow: none;
  }

  .markdown-body .progress {
    border: 1px solid #ddd;
  }

  .markdown-body .progress-bar {
    height: 22px;
    border-right: 1px solid #ddd;
  }

  .markdown-body tr,
  .markdown-body img {
    page-break-inside: avoid;
  }

  .markdown-body img {
    max-width: 100% !important;
  }

  .markdown-body p,
  .markdown-body h2,
  .markdown-body h3 {
    orphans: 3;
    widows: 3;
  }

  .markdown-body h2,
  .markdown-body h3 {
    page-break-after: avoid;
  }
}
</style><style>/*github*/
.codehilite {background-color:#fff;color:#333333;}
.codehilite .hll {background-color:#ffffcc;}
.codehilite .c{color:#999988;font-style:italic}
.codehilite .err{color:#a61717;background-color:#e3d2d2}
.codehilite .k{font-weight:bold}
.codehilite .o{font-weight:bold}
.codehilite .cm{color:#999988;font-style:italic}
.codehilite .cp{color:#999999;font-weight:bold}
.codehilite .c1{color:#999988;font-style:italic}
.codehilite .cs{color:#999999;font-weight:bold;font-style:italic}
.codehilite .gd{color:#000000;background-color:#ffdddd}
.codehilite .ge{font-style:italic}
.codehilite .gr{color:#aa0000}
.codehilite .gh{color:#999999}
.codehilite .gi{color:#000000;background-color:#ddffdd}
.codehilite .go{color:#888888}
.codehilite .gp{color:#555555}
.codehilite .gs{font-weight:bold}
.codehilite .gu{color:#800080;font-weight:bold}
.codehilite .gt{color:#aa0000}
.codehilite .kc{font-weight:bold}
.codehilite .kd{font-weight:bold}
.codehilite .kn{font-weight:bold}
.codehilite .kp{font-weight:bold}
.codehilite .kr{font-weight:bold}
.codehilite .kt{color:#445588;font-weight:bold}
.codehilite .m{color:#009999}
.codehilite .s{color:#dd1144}
.codehilite .n{color:#333333}
.codehilite .na{color:teal}
.codehilite .nb{color:#0086b3}
.codehilite .nc{color:#445588;font-weight:bold}
.codehilite .no{color:teal}
.codehilite .ni{color:purple}
.codehilite .ne{color:#990000;font-weight:bold}
.codehilite .nf{color:#990000;font-weight:bold}
.codehilite .nn{color:#555555}
.codehilite .nt{color:navy}
.codehilite .nv{color:teal}
.codehilite .ow{font-weight:bold}
.codehilite .w{color:#bbbbbb}
.codehilite .mf{color:#009999}
.codehilite .mh{color:#009999}
.codehilite .mi{color:#009999}
.codehilite .mo{color:#009999}
.codehilite .sb{color:#dd1144}
.codehilite .sc{color:#dd1144}
.codehilite .sd{color:#dd1144}
.codehilite .s2{color:#dd1144}
.codehilite .se{color:#dd1144}
.codehilite .sh{color:#dd1144}
.codehilite .si{color:#dd1144}
.codehilite .sx{color:#dd1144}
.codehilite .sr{color:#009926}
.codehilite .s1{color:#dd1144}
.codehilite .ss{color:#990073}
.codehilite .bp{color:#999999}
.codehilite .vc{color:teal}
.codehilite .vg{color:teal}
.codehilite .vi{color:teal}
.codehilite .il{color:#009999}
.codehilite .gc{color:#999;background-color:#EAF2F5}
</style><title>pharmacokinetic_modelling</title></head><body><article class="markdown-body"><h1 id="id">Modelling<a class="headerlink" href="#id" title="Permanent link"></a></h1>
<blockquote>
<p>Explain the concept of pharmacokinetic modeling of single and multiple compartment models.</p>
</blockquote>
<p><strong>Pharmacokinetics</strong> describes what the body does to a drug. Pharmacokinetic models are mathematical concepts used to predict plasma concentrations of drugs at different time points.</p>
<h2 id="basic-phamacokinetic-terms">Basic Phamacokinetic Terms<a class="headerlink" href="#basic-phamacokinetic-terms" title="Permanent link"></a></h2>
<p>Key concepts in pharmacokinetics include:
* <strong>Volume of distribution, V<sub>D</sub></strong><br />
The volume of distribution is defined as the <strong>theoretical volume into which an amount of drug would be distribute to produce the observed plasma concentration</strong>.
    * Units are ml.kg<sup>-1</sup> 
        * $$ Vd = {Total \ bioavailable \ drug \over Plasma \ concentration } $$ 
    * It is a way to describe what proportion of a drug is confined to plasma, and what proportion distributes to other tissues
    * It does not correspond to any particular volume, however a V<sub>D</sub> of:
        * Less than 40ml.kg<sup>-1</sup> indicates a drug is confined to plasma
        * Up to 200ml.kg<sup>-1</sup> indicates a drug is confined to the ECF
        * Up to 600ml.kg<sup>-1</sup> indicates a drug is dissolved into the TBW
        * Greater than 1L.kg<sup>-1</sup> indicates a drug is highly protein bound or lipophilic<br />
        Agents which cross the blood brain barrier typically have a V<sub>D</sub> of 1-2L.kg<sup>-1</sup>.
    * Subtypes of the volume of distribution are used to describe drug distribution at different times or with different models
        * These include:
            * V<sub>1</sub><br />
            Volume of central compartment.
            * V<sub>D</sub>ss<br />
            Volume of distribution at steady state.
            * V<sub>D</sub>pe<br />
            Volume of distribution at peak effect.
        * Which volume to use depends on the pharmacological question
            * e.g. Intubating dose for opioid should use a volume between V<sub>1</sub> (very small) and V<sub>D</sub>ss (very large) - V<sub>D</sub>pe is ideal as it will allow a target concentration to be selected for the time at which intubation will occur relative to drug administration</p>
<ul>
<li>
<p><strong>Half-life</strong> (t<sub>1/2</sub>)<br />
The time it takes for a process to be 50% complete. With respect to drug clearance, it is the time it takes for concentration (typically in plasma) to fall by 50%.</p>
<ul>
<li>A process is considered to be complete after 4-5 half-lives<br />
Concentration will decrease by 50% after each half-life, so after 5 half-lives concentration will be 3.125% of its starting value.<ul>
<li>This also applies to wash in - it will take ~4-5 elimination half-lives of a drug for a constant-rate infusion to reach its final concentration</li>
</ul>
</li>
<li>Half-life is mathematically related to many other key pharmacokinetic terms:<br />
$$t_{1/2} = 0.693 \times \tau = {0.693 \over k} = {0.693 \times V_D \over Cl}$$, where:<ul>
<li>$$\tau$$ is the time constant</li>
<li>$$k$$ is the rate constant for elimination</li>
<li>$$V_D$$ is the volume of distribution</li>
<li>$$Cl$$ is the clearance</li>
</ul>
</li>
<li>Various types of half-life are described:<ul>
<li>t<sub>1/2</sub>α describes the rapidity of the distribution phase following drug administration</li>
<li>t<sub>1/2</sub>β describes the rapidity of the <em>elimination</em> phase occurring after drug distribution equilibrium<br />
This only evaluates clearance from plasma, and so is a composite of both excretion from the body (e.g. renal and hepatic clearance) and ongoing distribution to peripheral tissues.<ul>
<li>The elimination half-life is generally not useful to predict drug offset, as this is affected by many factors<br />
However, it does set an <strong>upper limit</strong> on how long it will take plasma concentration to fall by 50%.</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p><strong>Time-constant</strong> ($$\tau$$)<br />
The time taken for a process to complete if it continued at its initial rate of change. Time constants are related to half-life, but are better suited when modelling change in exponential processes.</p>
<ul>
<li>Time constants are discussed in more detail under <a href="///C://Users/cjdba/Documents/GitHub/Part-One/time-constants.md">respiratory time constants</a></li>
<li>Elimination will be virtually complete after three time constants</li>
<li>A time constant is the <strong>inverse of the rate constant for elimination</strong>, i.e. $$ \tau = {1 \over k }$$</li>
<li>Illustration of the relationship between half-life and time constant:<br />
<img src="///C://Users/cjdba/Documents/GitHub/Part-One/resources/half-life-and-time-constants.svg">  </li>
</ul>
</li>
<li>
<p><strong>Clearance</strong><br />
The clearance is volume of plasma completely cleared of a drug per unit time.</p>
<ul>
<li>In a one compartment model, this can be expressed as: $$ Cl = k.V_D $$ in ml.min<sup>-1</sup>.<ul>
<li>As the <strong>time constant</strong> is the inverse of <strong>k</strong>, clearance can also be expressed as: $$ Cl = {V_D \over \tau } = {0.693 \times V_D \over t_{1/2}} $$</li>
</ul>
</li>
<li>Since $$k$$ and $$V_D$$ are constants, clearance is also a constant</li>
<li>Total clearance is a sum of the clearance of each individual clearance organ</li>
</ul>
</li>
<li>
<p><strong>Rate of elimination</strong><br />
Amount of drug removed by the body per unit time.</p>
<ul>
<li>Rate of elimination is the product of the clearance and the current concentration: $$ Rate \ of \ Elimination = Cl \times C $$, in mg.min<sup>-1</sup></li>
<li>This is not the rate constant for elimination</li>
</ul>
</li>
</ul>
<h2 id="compartmental-modellingone">Compartmental Modelling{#one}<a class="headerlink" href="#compartmental-modellingone" title="Permanent link"></a></h2>
<p>The simplest model imagines the body a single, well-stirred compartment. </p>
<p><img src="///C://Users/cjdba/Documents/GitHub/Part-One/resources/1compartment.svg" style="width: 10pc;"></p>
<p>In a one compartment model, the concentration of a drug ($$C$$) at time $$t$$ is given by the equation:</p>
<p>$$ C = C_0 e^{-kt} $$</p>
<p>Where:
<em> $$C_0$$ is the concentration at time 0<br />
As drug can only be eliminated from the compartment, this is also the peak concentration.
</em> <strong>k</strong> is the <strong>rate constant for elimination</strong><br />
This is the fraction of the Vd from which the drug is removed per unit time. The rate constant <strong>determines</strong> the <strong>slope</strong> of the curve.
    * A high rate constant for elimination results in a steep curve and therefore a short time constant</p>
<h3 id="steady-state">Steady state<a class="headerlink" href="#steady-state" title="Permanent link"></a></h3>
<p>At steady state, <strong>input is equal to output</strong>. Therefore concentration at steady state is:
<em> Proportional to the concentration of the infusion and infusion rate
</em> Inversely proportional to the clearance:<br />
$$\begin{array}{l} Input = Output \ C_i.I = C_{ss}.Cl \ C_{ss} = {C_i.I \over Cl} \end{array}$$<br />
    * Concentration of drug can therefore be determined by the amount infused and the clearance
* Note steady state requires peripheral compartments to be saturated, and so will only occur after an infusion of many hours</p>
<h3 id="multiple-compartment-modelsmulti">Multiple Compartment Models{#multi}<a class="headerlink" href="#multiple-compartment-modelsmulti" title="Permanent link"></a></h3>
<ul>
<li>Models with multiple compartments have a better fit with experimental data than single compartment models</li>
<li>Three-compartment models are typically used, as additional compartments typically offer no extra fidelity but are mathematically more complex</li>
<li>A three-compartment model <em>can</em> be conceptualised as a plasma (or central) compartment, a well-perfused compartment, and a poorly-perfused compartment<br />
This doesn&rsquo;t mean that they <em>should</em> be thought of in this way - they are a mathematical technique used to calculate plasma concentration at a given time.</li>
</ul>
<p><img src="///C://Users/cjdba/Documents/GitHub/Part-One/resources/3compartment.svg"></p>
<p>Plasma concentration in multicompartment models is:
<em> Predicted through the net effect of several negative exponential equations  x
This is covered under two-compartment models below.
</em> Dependent on the effects of:
    * <strong>Distribution</strong> <br />
    Distribution describes the movement of drug from the central compartment (V<sub>1</sub>) to the peripheral compartment(s).
        * Rapid fall in plasma concentration of a drug after administration is generally due to distribution<br />
        Distribution is an important method for drug offset in short-acting drugs.
    * <strong>Redistribution</strong><br />
    Redistribution refers to the movement of drug from the peripheral compartment(s) back into plasma.
        * Drugs which have a large V<sub>D</sub> in a peripheral compartment tend to <strong>distribute quickly</strong> along this concentration gradient, and <strong>redistribute slowly</strong> back into plasma
        * Drugs which tend to <strong>distribute slowly</strong> tend to <strong>redistribute quickly</strong> once administration has ceased
    * <strong>Excretion</strong><br />
    Excretion is the removal of drug from the body. </p>
<h4 id="clearance-in-two-compartment-modelsbi">Clearance in Two-Compartment Models{#bi}<a class="headerlink" href="#clearance-in-two-compartment-modelsbi" title="Permanent link"></a></h4>
<p>Removal of drug in two-compartment models is via:
<em> Distribution from the central to the peripheral compartment
</em> Elimination from the central compartment
* This produces a <strong>bi-exponential</strong> fall in plasma concentration<br />
Consists of two phases:
    * Phase α<br />
    Distribution phase: A rapid decline in plasma concentration due to distribution to peripheral tissues.
    * Phase β<br />
    Elimination phase: Slow decline in plasma concentration due to:
        * Elimination from the body
        * Redistribution into plasma</p>
<p><img src="///C://Users/cjdba/Documents/GitHub/Part-One/resources/biexponent.svg"></p>
<p>This curve is given by the equation $$C = Ae^{-\alpha t} + Be^{-\beta t}$$, where:
<em> $$C$$ is the concentration of drug in plasma
</em> $$A$$ is the y-intercept of the distribution exponent<br />
Used to calculate distribution half-life.
<em> $$B$$ is the y-intercept of the elimination exponent<br />
Used to calculate elimination half-life.
</em> $$\alpha$$ is the rate constant for distribution<br />
The value of $$\alpha$$ is dependent on the ratio of rate constants for distribution and redistribution (i.e. $$k_{12} \over k_{21}$$).
    * If distribution greatly exceeds redistribution, the gradient of $$\alpha$$ will be very steep and plasma concentration will fall rapidly after administration
* $$\beta$$ is the rate constant for elimination  </p>
<ul>
<li>Note that the distribution and elimination curves appear straight because the y-axis is log-transformed<ul>
<li>If plasma concentration was plotted on the y-axis, then each of these curves would be a negative exponential (wash-out curve)</li>
</ul>
</li>
</ul>
<h4 id="effect-siteeffect">Effect Site{#effect}<a class="headerlink" href="#effect-siteeffect" title="Permanent link"></a></h4>
<p>Pharmacokinetic models typically display the plasma concentration.
<em> Clinically however, we are interested in drug concentrations at the site of action (e.g. the brain)
    * Concentration at the effect site (also known as biophase) is given by <strong>Ce</strong>
        * This cannot be measured, and so is a calculated value
    * Effect site concentration be different from plasma concentration (<strong>Cp</strong>) prior to reaching steady state<br />
    The delay between plasma and effect site concentrations is an example of hysteresis.
</em> The effect site can be modelled as an additional compartment in three-compartment models<br />
The effect site is modelled as a <strong>compartment of negligible volume</strong> contained <strong>within V<sub>1</sub></strong>, but does have rate constants
    * Effect site volume changes as V<sub>1</sub> changes
    * The k<sub>e1</sub> is the rate constant for drug diffusion from plasma into the effect site
    * The <strong>k<sub>e0</sub></strong> is the rate constant for elimination of drug <strong>from the effect site</strong><br />
    This is a theoretical elimination pathway - drug is not usually metabolised at the effect site.
        * The t<sub>1/2</sub>ke0 describes the effect-site equilibration time<br />
        It describes how rapidly the effect site reaches equilibrium with plasma.
            * A large ke0 (rapid drug flow) gives a short t<sub>1/2</sub>ke0
            * After one t<sub>1/2</sub>ke0, 50% of the final effect site concentration will be reached provided plasma concentration remains constant
        * <strong>A shorter t<sub>1/2</sub>ke0 indicates that that the effect site concentration will reach equilibrium with plasma more rapidly, and therefore a more rapid clinical effect following administration is seen</strong>
        * Note that:
            * The t<sub>1/2</sub>ke0 is not the time to peak effect
                * Neither is k<sub>e0</sub>
            * For an infusion run at constant plasma concentration the peak effect will be seen at 3-5x the t<sub>1/2</sub>ke0
            * The time to peak effect is a function of both plasma kinetics and the t<sub>1/2</sub>ke0
                * e.g. adenosine has such a short elimination t<sub>1/2<sub> the effect site concentration will reach its peak rapidly regardless of the k<sub>e0</sub></p>
<p><img src="///C://Users/cjdba/Documents/GitHub/Part-One/resources/3compartment%2Beffect.svg"></p>
<h2 id="non-compartmental-models">Non-Compartmental Models<a class="headerlink" href="#non-compartmental-models" title="Permanent link"></a></h2>
<p>Compartment models are not appropriate for describing the behaviours of all drugs. Non-compartmental models are used when drug:
<em> Clearance is organ-independent
</em> Elimination does not occur solely from the central compartment</p>
<p>These models use <strong>AUC</strong>, which is calculated by measuring the plasma concentration of a drug at different time intervals, and <strong>plotting the area under the curve (AUC)</strong>. This can be used to:
<em> Determine <strong>clearance</strong><br />
$$ Cl = {Dose \over AUC}$$
</em> Determine <strong>Bioavailability</strong><br />
Difference between the AUC of the same dose of drug administered IV and via another route.</p>
<hr />
<h2 id="footnotes">Footnotes<a class="headerlink" href="#footnotes" title="Permanent link"></a></h2>
<p>The formula for half-life can be derived from the equation for a wash-in exponential as follows:
<em> Wash in exponential is given by: $$C = 1 - e^{-kt}$$<br />
</em> $$y = 0.5$$ can then be substituted and the equation solved for $$t$$ as follows:<br />
$$Input = Output$$<br />
$$C_i.I = C_{ss}.Cl$$<br />
$$C_{ss} = {C_i.I \over Cl}$$</p>
<p>$$ \begin{align*}
0.5 &amp;= 1 - e^{-kt} \
 -0.5 &amp;= e^{-kt} \
\ln-0.5 &amp;= -kt \
\ln 2 &amp;= kt \
{\ln 2 \over k} &amp;= t \
{0.693 \over k} &amp;= t</p>
<p>\end{align*}$$</p>
<hr />
<h2 id="references">References<a class="headerlink" href="#references" title="Permanent link"></a></h2>
<ol>
<li>Peck TE, Hill SA. Pharmacology for Anaesthesia and Intensive Care. 4th Ed. Cambridge University Press. 2014.  </li>
<li>Plasma Volume.  Mosby&rsquo;s Medical Dictionary, 8th edition. 2009.  </li>
<li>Stanski RD, Shafer SL. <a href="https://web.stanford.edu/~sshafer/LECTURES.DIR/Notes/Biophase%20in%20Anesthesia.doc">The Biophase Concept and Intravenous Anesthesia</a>.</li>
<li>Petkov V. Essential Pharmacology For The ANZCA Primary Examination. Vesselin Petkov. 2012.</li>
</ol></article></body></html>